Your Tag: ATMPs (Advanced Therapy Medicinal Products)

ERDERA’s ethics and regulatory experts are launching a dedicated webinar series to help the rare disease research community navigate two fast-moving areas of biomedical research: Advanced Therapy Medicinal Products (ATMPs) and Artificial Intelligence.
ERDERA (the European Rare Diseases Research Alliance) has opened its Clinical Trial Call to support multinational early-phase clinical trials in rare diseases. The call will fund studies designed to generate robust clinical evidence, strengthen regulatory readiness and make rare disease trials more feasible across countries.
Call text draft setting out rules, eligibility and staged application process for the ERDERA Clinical Trial Call 2026.
ERDERA launches Clinical Trial Call 2026 to advance early‑phase clinical trials for rare diseases
The European Rare Diseases Research Alliance (ERDERA), together with the European Reference Networks (ERNs), provides the missing operational layer required to implement the European Biotech Act across the full innovation pathway —from discovery to patient access.
ERDERA will launch its Clinical Trial Call (ECTC) on 1 July 2026, supporting multinational, GCP‑compliant early‑phase interventional clinical trials in rare diseases.
Pre-announcement describing scope, eligibility and indicative timeline for the ERDERA Clinical Trial Call 2026, expected to open on 1 July 2026.
These guidelines explain the eligibility rules, submission process and Expression of Interest requirements for the ERDERA Clinical Trial Call.
This annex explains the specific eligibility, sponsorship, funding and application requirements for Canadian applicants in the ERDERA Clinical Trial Call.
This template lists the sections and fields applicants must complete for an Expression of Interest in the ERDERA Clinical Trial Call.